The new ruling will have no effect on access until the Supreme Court ultimately decides the case.
The price of the pill, which has not been announced, will determine how affordable it will be when it becomes available in early 2024.
The F.D.A. gave full approval to the drug, but added a black-box warning about safety risks. Medicare said it would cover most of the high cost.
The law was to take effect on July 1. It is the only state law that specifically outlaws the most common abortion method in the country.
The action, which stayed a lower court ruling, will require health plans to fully cover preventive services while the appeals process plays out.
In an unusual court trial, a federal jury sided with the drug maker Gilead Sciences in a dispute over who came up with the idea of using a daily pill to prevent H.I.V.
The judges blocked the drug from being sent to patients through the mail and rolled back other steps the government had taken to ease access.
One invalidated the F.D.A.’s approval of the abortion pill mifepristone. The other ordered the F.D.A. to do nothing to restrict the pill’s availability.
A ruling by a federal judge this week could set up yet another Supreme Court challenge to the Obamacare health law.
Information and medications needed to end a pregnancy are increasingly available outside the health care system.